HCW Biologics earns $7M upfront license fee from WY Biotech for HCW11-006

HCW Biologics Inc.

$7.0M upfront fee earned; revenue to be recognized in Q2 2025.
WY Biotech completed due diligence and confirmed commitment; agreement now fully binding.
HCWB eligible for additional development milestones and double-digit royalties on future sales.
HCWB has opt-in rights to recapture development/commercialization rights in U.S., Canada, Central and South America after Phase 1.
WY Biotech bears all R&D, manufacturing, clinical, and commercialization costs; HCWB responsible only if it exercises opt-in.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.